Braveheart Bio discloses 7.42M preferred shares held

Braveheart Bio, Inc. reports that Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a more-than-10% owner through 7,420,091 shares of non-voting Series A preferred stock.

Accepted by SEC EDGAR 08/06/2026 - 06:02 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Braveheart Bio, Inc. reports that Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a more-than-10% owner through 7,420,091 shares of non-voting Series A preferred stock. This Preferred Stock is convertible into an equal number of common shares at the holder’s election and has no expiration date. All Preferred Stock will automatically convert into common stock immediately prior to the closing of Braveheart Bio’s initial public offering of its common stock.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Role 10% Owner

Type	Security	Shares	Price	Value
Holding	Non-voting Series A preferred stock F1	--	--	--

Holdings: Non-voting Series A preferred stock — 7,420,091 shares (Direct)

Footnotes (1)

1. F1. The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock will automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

Key Figures

Preferred shares held: 7,420,091 shares Underlying common shares: 7,420,091 shares

2 metrics

Preferred shares held 7,420,091 shares Non-voting Series A preferred stock held directly by Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Underlying common shares 7,420,091 shares Common stock underlying the Preferred Stock, convertible at the holder’s election

Key Terms

Non-voting Series A preferred stock, convertible into shares of Common Stock, initial public offering

3 terms

Non-voting Series A preferred stock financial

"The non-voting Series A preferred stock of the Issuer are convertible into shares of Common Stock"

convertible into shares of Common Stock financial

"are convertible into shares of Common Stock of the Issuer at the holder's election"

initial public offering financial

"will automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership does Jiangsu Hengrui hold in Braveheart Bio (BRVE)?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. holds 7,420,091 shares of Braveheart Bio’s non-voting Series A preferred stock, representing a more-than-10% ownership position disclosed in this initial insider report.

What type of security does Jiangsu Hengrui own in Braveheart Bio (BRVE)?

Jiangsu Hengrui owns non-voting Series A preferred stock of Braveheart Bio, which is convertible into the company’s common stock on a one-for-one basis at the holder’s election, according to the disclosure.

Can Jiangsu Hengrui convert its Braveheart Bio (BRVE) preferred shares to common stock?

Yes. The Preferred Stock is convertible into common stock at the holder’s election and has no expiration date, providing flexibility for Jiangsu Hengrui to switch into common equity in the future.

When will Braveheart Bio’s Preferred Stock automatically convert to common stock?

All non-voting Series A preferred shares will automatically convert into common stock immediately prior to the closing of Braveheart Bio’s initial public offering of its common stock, as described in the footnote.

Does the Braveheart Bio (BRVE) preferred stock held by Jiangsu Hengrui have an expiration date?

No. The non-voting Series A preferred stock held by Jiangsu Hengrui has no expiration date, and remains outstanding until converted into common stock under the terms described.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

(Last) (First) (Middle)

7 KUNLUNSHAN RD, ECON. & TECH. DEV. ZONE

(Street)

LIANYUNGANG JIANGSU 222000

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/05/2026

3. Issuer Name and Ticker or Trading Symbol
Braveheart Bio, Inc. [ BRVE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-voting Series A preferred stock	(1)	(1)	Common Stock	7,420,091	(1)	D

Explanation of Responses:

1. The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock will automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

	Jiangsu Hengrui Pharmaceuticals Co., Ltd. /s/ Lau Kin Chun, Chief Financial Officer, on behalf of Jiangsu Hengrui Pharmaceuticals Co., Ltd.	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)